UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
Medicines Bill Introduced To Parliament
Executive Summary
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.
You may also be interested in...
Hunt On For New Chair Of UK Regulator
Whoever takes over as chair of the Medicines and Healthcare products Regulatory Agency will play a key role in its plans to deliver a program of “ambitious business change.”
Hunt On For New Chair Of UK Regulator
Whoever takes over as chair of the Medicines and Healthcare products Regulatory Agency will play a key role in its plans to deliver a program of “ambitious business change.”
Yet More Delay For EU Clinical Trial Regulation
Revisions and restructuring of the contract with the developers mean that Europe’s new clinical trials system will not go live next year as planned, although the European Medicines Agency says progress has been made with development of the system.